A novel SPECT/CT acquisition method utilizing lead-212 (212Pb) accurately detects radiopharmaceutical biodistribution in prostate cancer patients, potentially revolutionizing treatment by offering precision imaging and increasing global access, as reported in The Journal of Nuclear Medicine.
New research reveals that peptide receptor radionuclide therapy effectively controls symptoms and reduces medication dependency in metastatic insulinoma patients, marking a significant advancement in treatment options for this rare and life-threatening condition.
A newly developed PET radiotracer can be used to create an inflammation map of the entire gastrointestinal tract, providing detailed information to accurately detect and stage inflammatory bowel disease.
The Medical Imaging & Technology Alliance (MITA), CORAR Inc., and SNMMI have garnered support from 123 organizations for the FIND Act of 2023, aiming to improve patient access to innovative nuclear medicine and address Medicare payment issues.
Read More
A new pre-targeted radioimmunotherapy system, targeting the HER2 protein in ovarian cancer, has demonstrated potential in curing a lethal form of advanced intraperitoneal ovarian cancer with minimal side effects in a preclinical study.
Read More
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute in Salt Lake City announces that it is the first in the U.S. to install United Imaging’s uMI Panorama PET/CT scanner.
Read More
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer patients being treated with 177Lu-PSMA radionuclide therapy.
Read More
Researchers at the University of Wisconsin, Madison, have achieved a breakthrough in the production of scandium radioisotopes, a development with profound implications for the future of medical imaging and cancer treatment.
Read More